Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. - Wikidata - wikimedia - TriplyDB

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

http://www.wikidata.org/entity/Q35992076

about

Progress and challenges in screening for early detection of ovarian cancer.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence Increased CA 125 serum levels in patients with advanced acute leukemia with serosal involvement.Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases.Treating ovarian cancer.Serum CA 125 levels in children with non-Hodgkin's lymphoma.Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling Colorimetric immunoassay for detection of tumor markers.The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.Comparison of candidate serologic markers for type I and type II ovarian cancer Plasma immune analytes in patients with epithelial ovarian cancer.Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers CA 125 half-life in ovarian cancer: a multivariate survival analysis Elevated CA125 levels in patients with metastatic breast carcinoma.CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer.A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.Application of tumor markers in ovarian malignancies.CA125 in ovarian tumour tissue at second laparotomy.The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.Biomarker approaches to the development of cancer screening tests: can cancer blood tests become a routine health check-up?Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.Clinical significance of serum CA-125 in Korean females with ascites Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.CA 125 secretion by peritoneal mesothelial cells Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer.Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.Endometrial cancer: multiplexed Luminex approaches for early detection.Clinical utility of antigen carbohydrate 125 in heart failure.Recent progress in the immunological monitoring of carcinomas using monoclonal antibodies.Present status of serum tumor markers in diagnosis, prognosis, and evaluation of therapy.Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.

P2860

Q31041170-212BD527-C598-4E83-B03E-4BA59D0D2B71 Q33759991-B1EC50B3-2F2E-4C81-8D25-6680A497B195 Q33807723-458A48C7-36C1-451D-9293-DC69C6C5DA6C Q33838899-547402D4-07CF-48FC-8275-1568B6990F23 Q33941562-4A3D7FF0-2AC0-4BD4-AF93-B3808C0CA92D Q34092935-BBA82AE5-A190-4B7A-AF50-F57E4F1BA458 Q34289329-06E11E7A-360D-4091-A914-8E2CF9A90CC1 Q34504249-E44F48DE-AC2D-49DB-92F6-2A14E33B92D1 Q34727254-5899080C-BA04-4AC8-B2F4-2157673E44DD Q34991249-519A1DA9-9D31-49F6-9780-726AFA5D8C5D Q35002196-4202F74B-5B87-4387-8225-B33F71BDECD2 Q35094175-26912624-A75E-4A00-82F5-BB9568B21081 Q35154077-4954D6AC-12E1-416A-9698-065BCAFFEE33 Q35236090-BC0C2991-7F9E-4CBE-8A51-FE5ECC3442D9 Q35677625-5B97386C-F207-4720-AD53-AA4CE0DEA14E Q35975732-D97298EC-B979-40AD-80EA-BCFAC0186A37 Q35977003-70D1658F-0344-4C47-B5A3-F55462760182 Q35982073-45F3D2E8-6ACF-4891-A4C0-55135AAE654A Q35992490-D9A3C1AB-1B5B-495D-8159-1FDC6721EEEC Q35993486-64A881A9-E0AB-4D97-88E4-E835E203C348 Q36027722-BC20D641-49D1-46F0-B697-352458C66695 Q36264321-E396A02C-6B3B-4EED-BBE1-2DF7556F70B9 Q36467114-2020AC44-FDFC-483B-9774-B010BEFCCC9D Q36467455-B12B08B8-1E56-49CA-AD53-03E6F3BD9F9D Q36619691-58CF04D4-3CE2-4339-B648-5A45B6E9A60F Q36839774-6C579FB9-CEE2-48BC-8DE6-83461D6E7A19 Q36987742-576F17F7-0C6A-4064-AB9F-A40626221D80 Q37094675-8F4A0BEE-E79F-49FB-AA0A-1DDE26AE14D7 Q37177686-A6EDAF7E-FE8E-48F6-A509-B282D2C2FDFD Q37248310-3212A2CF-ED66-4B86-87B2-CA455E70FD0C Q37340571-07C10CCE-1DCA-4AE3-BBF8-CE8C9A624E7B Q37551343-69E56AAC-4DE1-49C3-B0B2-F0F5EAEDC1C9 Q37564665-CDCA9CE7-0BBF-41AC-BD04-FC586990C583 Q37701232-95E88CAB-B58D-465C-8485-79C90354AE4C Q37873930-DC6F91AF-6057-4F6C-A597-B88D028E3A95 Q38089759-A3324805-A9AE-41F3-837A-D375931B0241 Q38127350-A466A817-9EEF-4C5D-AFED-917E45CF56C2 Q38159260-BAC785A8-DB43-4977-BFE0-8768CB63B0F0 Q38168123-2B4DE9AD-C4E8-49DA-8BEF-426D907B6766 Q38470014-6B86498E-C695-4FE8-9FF0-D4191D4D7495

P2860

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

http://www.wikidata.org/entity/Q35992076

description

1984 nî lūn-bûn

@nan

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

1984年论文

@zh

1984年论文

@zh-cn

name

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@ast

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@en

type

label

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@ast

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@en

prefLabel

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@ast

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@en

P1433

Q35992076-29391A66-FAB0-4A22-92ED-6D751CD05707

P1476

Q35992076-FCFC0410-F9E3-474C-BDA5-CC80BFD40B2F

P2093

Q35992076-07F96B7A-9771-4FBB-9E9E-08A5A44FEE73

Q35992076-2A15F982-9D2E-4D71-8A57-00046FDFA2AD

Q35992076-4610D2AE-8987-4239-B46F-12B501FD4466

Q35992076-E84F79EC-3F45-4AD5-A24D-DCB9DE5FEAD3

P2860

Q35992076-03A88478-E19C-46C3-A6C6-023B72FD3F0E

Q35992076-54827875-BF4E-4E8D-B876-2A15B436B7D2

Q35992076-6EDDF1F0-6E25-490C-8DDC-673FA6CCE93A

Q35992076-D4FB0274-A169-4094-B64F-24DD55FD30F5

P2888

Q35992076-81C01CDC-423F-4508-9226-61249C1154DC

P304

Q35992076-7205CA8E-D749-46CB-A852-ADDA21D00E85

P31

Q35992076-140516DF-6C9D-45FE-B3DF-EC7936B52320

P356

Q35992076-EF11CC7A-054F-4AEA-8A4E-E5B5658DEFB6

P407

Q35992076-EF026A3A-9096-4E89-9F7F-28722A37A984

P433

Q35992076-30D26706-7CC5-44C1-B18A-870A51E9B668

P478

Q35992076-24AA18F1-B6F8-4D31-B1F8-088AA0A64227

P577

Q35992076-ABE027EF-94E8-4D5D-98F6-CAD84FE924C9

P5875

Q35992076-65AAC3F2-2D84-4F01-A527-90112D327683

P6179

Q35992076-199BAE32-2984-4EC2-838F-06BCCA89B6DA

P698

Q35992076-B9063028-7431-4CB8-928C-67A5E0C3D4C4

P921

Q35992076-DBBED6D7-CABC-4224-816E-F09C257908A7

P932

Q35992076-85C2C786-2950-4C8B-BF75-4C75F33641B5

P356

P1433

British Journal of Cancer

P1476

Ovarian cancer antigen CA125: ...... f its role as a tumour marker.

@en

P2093

Canney PA

http://www.w3.org/2001/XMLSchema#string

James RD

http://www.w3.org/2001/XMLSchema#string

Moore M

http://www.w3.org/2001/XMLSchema#string

Wilkinson PM

http://www.w3.org/2001/XMLSchema#string

P2860

Reactivity of a monoclonal antibody with human ovarian carcinoma

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Chemotherapy of advanced malignant teratomas

Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

P2888

P304

765-769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1984.254

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

1984-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

16987194

http://www.w3.org/2001/XMLSchema#string

P6179

1017095971

http://www.w3.org/2001/XMLSchema#string

P698

6208925

http://www.w3.org/2001/XMLSchema#string

P921

P932

1977011

http://www.w3.org/2001/XMLSchema#string